Biomarkers play a pivotal role in modern life science research, from identifying disease signatures to guiding therapeutic development and monitoring treatment response. In this multi-perspective webinar, hear from experts applying unique strategies, tools, and analytical techniques to move biomarker discovery and application forward.

Sarah Kotanchiyev, MLS (ASCP)CM
Field Application Scientist, Slingshot Biosciences

Sarah Kotanchiyev, MLS (ASCP)CM will discuss how Slingshot Biosciences’ precision-engineered cell mimics are advancing biomarker-driven research. These innovative controls provide a more reliable, reproducible, and scalable alternative to biological controls, reducing variability in biomarker assays and improving standardization across flow cytometry and other cell-based applications.

Sunghyun Huh, PhD
Head of Bioinformatics, Bertis Inc.

During the webinar, Sunghyun Huh,PhD will present key insights into three critical areas. First, he will demonstrate omics analysis, with a particular focus on the proteomic approach for uncovering biological phenomena. Second, he will highlight strategies for identifying disease-specific biomarkers, which have the potential to serve as both diagnostic and therapeutic signatures. Lastly, the presentation will delve into deciphering the molecular mechanisms underlying these biomarkers, providing a clearer understanding of their efficacy and applicability in clinical settings. Each topic will be presented with study cases conducted at Bertis.

Julie Ann Mayer, PhD
Vice President, Global Biomarker Platform, Crown Bioscience

Join Julie to delve into the evolving landscape of clinical biomarker services and translational oncology solutions. She will explore how an integrated approach – combining access to clinically relevant tumor materials with advanced biomarker analysis – unlocks deeper insights into cancer biology and therapeutic response. Discover real-world applications and case studies that demonstrate how Crown’s end-to-end services are accelerating oncology drug development, from early discovery through clinical translation.

Key Topics Include:

  • Understand how cell mimics overcome challenges with biological controls to improve biomarker assay reliability.
  • Learn how ViaComp® and SpectraComp™ controls enhance standardization, stability, and reproducibility in flow cytometry-based biomarker detection.
  • Utilizing proteomic analysis to identify phenotypic signatures associated with disease states and biological processes.
  • Deciphering molecular mechanisms underlying identified signatures to provide a deeper understanding of disease physiology and pathophysiological pathways.
  • Discover how Crown Bioscience sources and applies clinically relevant biospecimens as part of a broader biomarker service offering to drive discovery and validation.
  • Explore how predictive and pharmacodynamic biomarker strategies are applied to streamline cancer drug development and enable effective patient stratification.
  • Learn how Crown’s comprehensive service portfolio—including biospecimen access, molecular profiling, and clinical biomarker analysis—advances translational oncology programs.

Presenters

Sarah Kotanchiyev, ;MLS (ASCP)CM

Sarah Kotanchiyev, MLS (ASCP)CM

Field Application Scientist - Manager
Slingshot Biosciences

Sarah Kotanchiyev, MLS (ASCP)CM has a background of over 8 years of experience in clinical flow cytometry at Emory University Hospital where she was heavily involved in new assay development, validation, and implementation. She was the initial field applications scientist at Slingshot and has grown the position over the past two and a half years to better serve our customers. In her role she plays a key role in assisting customers with implementing our catalog and custom products into their workflow for more streamlined efficiency.
Sunghyun Huh, ;PhD

Sunghyun Huh, PhD

Head of Bioinformatics
Bertis Inc.

Dr. Sunghyun Huh is the Head of the Biomedical Informatics team at Bertis Inc., specializing in biomarker discovery and systems biology analysis to support the company's diagnostic assay development and analytic service. With a strong background in bioinformatics using mass spectrometry-based proteomics data, he holds a Ph.D. in systems biology from DGIST (Daegu Gyeongbuk Institute of Science and Technology). Prior to joining Bertis, Sunghyun worked as a post-doctoral researcher at Seoul National University and as a student researcher at IBS (Institute for Basic Science), gaining extensive experience in multi-omics data analysis spanning various biological systems and topics.
Julie Ann Mayer, ;PhD

Julie Ann Mayer, PhD

Vice President, Global Biomarker Platform
Crown Bioscience

Dr. Julie Ann Mayer has held progressive scientific and leadership roles spanning R&D and Operations at several molecular diagnostics companies, including NeoGenomics Laboratories, Biocept Inc., and Navigate BioPharma Services (a Novartis subsidiary). She has extensive precision medicine experience, having developed, validated, and launched >50 diagnostic assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories. Before joining industry, Dr. Mayer received her post-doctoral training in translational breast cancer research at Baylor College of Medicine and in clinical cancer prevention at MD Anderson Cancer Center and obtained her Ph.D in Pathology from the University of Southern California.
Watch Webinar

Production Partner

Slingshot Biosciences

Slingshot Biosciences develops cell mimics that serve as consistent, customizable controls for cell-based assays. Their products are designed to replace traditional biological controls in applications such as flow cytometry, diagnostics, and instrument calibration. By using engineered particles that simulate cell properties, Slingshot enables more standardized and reproducible experiments without relying on donor-derived materials.

VIEW PROFILE
Slingshot Biosciences

Bertis Inc.

Bertis is a biotechnology company focused on developing proteomics-based diagnostic solutions and biomarker discovery tools. By combining high-throughput proteomic analysis with advanced data science, Bertis aims to support early disease detection and personalized healthcare. Their offerings include MASTOCHECK, a clinically validated blood test for early breast cancer detection, and the Pan-omics Analysis Service & Solution (PASS), which provides integrative multi-omics analysis for research and clinical development. Bertis collaborates with healthcare and life science partners worldwide to apply proteomics to real-world medical challenges.

VIEW PROFILE
Bertis Inc.

Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology.

VIEW PROFILE
Crown Bioscience

Additional Content From Crown Bioscience

Additional Content From Scientist.com

Related Content